← Eichor
Study identifier: NCT06632457 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Condition: Metabolic Dysfunction Associated Steatohepatitis  ·  Sponsor: Boehringer Ingelheim

PhasePhase 3
Planned participants1590
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the …

This description comes directly from the study's public registry record.

Talk to the study team

Boehringer Ingelheim  ·  1-800-243-0127  ·  clintriage.rdg@boehringer-ingelheim.com

Always discuss trial participation with your own doctor first.

Locations (444)

The Institute for Liver Health II DBA Arizona Clinical TrialsPeoria, Arizona, United StatesRecruiting
Scottsdale Medical Specialists, LtdScottsdale, Arizona, United StatesRecruiting
Adobe Clinical Research, LLCTucson, Arizona, United StatesNot Yet Recruiting
Arizona Liver Health - TucsonTucson, Arizona, United StatesRecruiting
Del Sol Research Management, LLCTucson, Arizona, United StatesRecruiting
Hope Clinical ResearchCanoga Park, California, United StatesRecruiting
Velocity Clinical Research-Chula VistaChula Vista, California, United StatesRecruiting
Southern California Research CenterCoronado, California, United StatesRecruiting
ARK Clinical ResearchFountain Valley, California, United StatesRecruiting
Velocity Clinical Research-Huntington ParkHuntington Park, California, United StatesNot Yet Recruiting
310 Clinical ResearchInglewood, California, United StatesRecruiting
Velocity Clinical Research, San DiegoLa Mesa, California, United StatesNot Yet Recruiting

+ 432 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06632457